Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Get Free Report) shares shot up 5% during trading on Friday. The stock traded as high as $17.26 and last traded at $17.6380. 124,335 shares traded hands during mid-day trading, a decline of 94% from the average daily volume of 2,167,842 shares. The stock had previously closed at $16.80.
Analyst Upgrades and Downgrades
A number of equities analysts have weighed in on the stock. Wells Fargo & Company reduced their price objective on shares of Tandem Diabetes Care from $27.00 to $25.00 and set an “overweight” rating for the company in a research report on Friday, November 6th. Barclays raised their price objective on Tandem Diabetes Care from $18.00 to $20.00 and gave the company an “equal weight” rating in a report on Friday, November 6th. Mizuho set a $20.00 price objective on Tandem Diabetes Care in a research report on Friday, November 6th. UBS Group upgraded Tandem Diabetes Care from a “neutral” rating to a “buy” rating in a research report on Wednesday. Finally, Canaccord Genuity Group set a $40.00 target price on Tandem Diabetes Care in a research note on Friday, August 7th. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $27.39.
Read Our Latest Research Report on Tandem Diabetes Care
Tandem Diabetes Care Trading Up 4.2%
The stock has a market cap of $1.22 billion, a PE ratio of -24.28 and a beta of 1.59. The business has a 50-day moving average of $17.24 and a 200 day moving average of $18.79. The company has a debt-to-equity ratio of 4.47, a quick ratio of 2.65 and a current ratio of 3.20.
Tandem Diabetes Care (NASDAQ:TNDM – Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The medical device company reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.15. The company had revenue of $283.69 million during the quarter, compared to the consensus estimate of $265.85 million. Tandem Diabetes Care had a negative net margin of 4.58% and a negative return on equity of 35.61%. The company’s quarterly revenue was up 13.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.31) EPS. Equities research analysts predict that Tandem Diabetes Care, Inc. will post -0.61 EPS for the current fiscal year.
Insiders Place Their Bets
In related news, Director Christopher J. Twomey sold 1,700 shares of Tandem Diabetes Care stock in a transaction dated Tuesday, October 27th. The stock was sold at an average price of $19.15, for a total value of $32,555.00. Following the completion of the transaction, the director directly owned 24,434 shares in the company, valued at approximately $467,911.10. This trade represents a 6.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.10% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On Tandem Diabetes Care
Institutional investors and hedge funds have recently modified their holdings of the stock. Integrated Wealth Concepts LLC acquired a new position in Tandem Diabetes Care in the 2nd quarter valued at approximately $33,000. Sterling Capital Management LLC grew its holdings in Tandem Diabetes Care by 849.0% during the third quarter. Sterling Capital Management LLC now owns 2,325 shares of the medical device company’s stock valued at $38,000 after purchasing an additional 2,080 shares during the period. Fulcrum Asset Management LLP boosted its stake in shares of Tandem Diabetes Care by 1,463.6% during the 3rd quarter. Fulcrum Asset Management LLP now owns 4,378 shares of the medical device company’s stock worth $73,000 after acquiring an additional 4,098 shares during the period. Prosperitas Financial LLC acquired a new stake in Tandem Diabetes Care during the second quarter worth approximately $151,000. Finally, Provenance Wealth Advisors LLC bought a new position in shares of Tandem Diabetes Care in the third quarter worth about $158,000.
About Tandem Diabetes Care
Tandem Diabetes Care develops and commercializes technology for people who use insulin to manage diabetes. Its products include insulin pumps, infusion sets and related supplies, along with software for viewing and sharing diabetes-management data. The company’s offerings include the t:slim X2 insulin pump and the Tandem Mobi pump, as well as Control-IQ technology, which can automatically adjust insulin delivery based on continuous glucose monitor readings when used with compatible devices. Tandem also provides mobile apps and cloud-based tools to support users and healthcare providers.
Recommended Stories
- Five stocks we like better than Tandem Diabetes Care
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
- Cracks in the Crockery? Williams-Sonoma Insiders Sell Shares
Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.
